Table 1.
Clinicopathologic features among 18 patients for acquired MET amplification
| Characteristics | Number | Percentage (%) |
|---|---|---|
| Gender | ||
| Male | 7 | 38.9 |
| Female | 11 | 61.1 |
| Age (years) | ||
| Mean | 57 years | |
| < 60 | 10 | 55.6 |
| ≥ 60 | 8 | 44.4 |
| ECOG PS | ||
| 0–1 | 18 | 100 |
| 2 | 0 | 0 |
| Histologic type | ||
| Adenocarcinoma | 16 | 88.9 |
| Other | 2 | 11.1 |
| Smoking status | ||
| No | 12 | 66.7 |
| Yes | 6 | 33.3 |
| Type of EGFR mutation | ||
| 19 deletion | 2 | 11.1 |
| 21L858R | 16 | 88.9 |
| Type of EGFR-TKIs | ||
| Gefitinib | 10 | 55.6 |
| Elrotinib | 3 | 16.7 |
| Icotinib | 5 | 27.8 |
| Treatment lines of EGFR-TKI | ||
| First line | 12 | 66.7 |
| Second line or more | 6 | 33.3 |
| Met amplification | ||
| > 5 | 12 | 66.7 |
| 2.2–5 | 4 | 22.2 |
| 1.8–2.2 | 2 | 11.1 |
| Receiving crizotinib | ||
| Yes | 14 | 77.8 |
| No | 4 | 22.2 |